AN Venture Partners

AN Venture Partners Announces the Addition of Mikael Dolsten as Advisor

Press Release

AN Venture Partners Announces the Addition of Mikael Dolsten as Advisor

San Francisco, August 21, 2025

AN Venture Partners (ANV), a global biotech venture capital fund, today announced that Mikael Dolsen, a renowned global leader in pharmaceutical research and development is joining as an Advisor.

Ken Horne, Managing Partner, said: “We are delighted to have attracted someone of Mikael’s caliber to ANV. Our management team is committed to learning from the best and there are very few individuals in the pharma sector who can match Mikael’s track record in R&D and senior leadership. We look forward to benefiting from his experience.”

“I have always admired the strength and depth of Japanese science,” said Dr. Dolsten. “So, I am very happy to support a firm whose core mission is bringing that science to the world. ANV has assembled a great team in a very short period and I am impressed by their entrepreneurial drive. I am looking forward to seeing what we can achieve together.”

Profile

Mikael Dolsten, MD, PhD, Advisor

Dr. Mikael Dolsten is a renowned physician-scientist and global leader in pharmaceutical research and development. He recently retired from Pfizer Inc. after a distinguished 16-year tenure as Chief Scientific Officer and President of R&D, where he oversaw the regulatory approval of over 35 medicines and vaccines, and advanced more than 150 drug candidates into clinical studies. Dr. Dolsten played a pivotal role in the global response to the COVID-19 pandemic.

Previously, Dr. Dolsten held senior roles at Wyeth, Boehringer Ingelheim and AstraZeneca. Dr. Dolsten has venture capital experience from OrbiMed, ATP and Pfizer venture groups, and has participated in numerous corporate transactions exceeding $100 billion.

He currently serves on the public boards of Agilent Technologies, Novo Nordisk and Rocket Pharmaceuticals, and as chairman, board member, or advisor of several companies, including Orbis Medicines, Immunai, Arbor Biotechnologies, Blackstone, GV and Bains & Company. Dr. Dolsten has advised the Obama, Biden, Trump administrations on public health initiatives, as well as the UK Government’s G7 leadership for pandemic response.

About AN Venture Partners

ANV is a Tokyo and San Francisco-based multi-stage, global biotech venture capital firm specializing in bridging innovative science from Japan with the US start-up ecosystem. ANV Fund I is a USD200 million fund that closed in June 2025. The firm was established in 2022 by a group of experienced venture capitalists from Japan and the United States, who have a wealth of experience building start-ups. ANV is committed to strengthening Japan’s biotech ecosystem and founded initiatives such as Science2Startup Japan to accelerate ecosystem growth.

Media Contacts
Email: info@an.vc

AN Venture PartnersLinkedIn

Office Location

AN Venture GK

GLOBAL LIFESCIENCE HUB 7F, Nihonbashi Muromachi Mitsui Tower 3-2-1 Nihonbashi Muromachi, Chuo-ku Tokyo 103-0022, Japan

AN Venture PartnersAN Venture PartnersAN Venture PartnersAN Venture PartnersAN Venture PartnersAN Venture PartnersAN Venture PartnersAN Venture Partners

AN Venture Partners, Advancing Japanese Biotech Globally

Copyright © 2026 AN Venture Partners

Privacy Policy
This website uses Google Analytics cookies for access analysis only. The collected data is used solely for improving the website and is handled appropriately. By clicking "AGREE", you consent to the use of cookies.